-
New diabetes medication reduced heart event risk in those with diabetes and kidney disease
[ad_1] Research Highlights: Sotagliflozin – a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes…
Read More » -
Tauriga Sciences Inc. Extends its Relationship with Alibaba Group for a Period of an Additional 12 Months
[ad_1] NEW YORK, NY – (NewMediaWire) – November 16, 2020 – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a…
Read More » -
BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study
[ad_1] Announces Promotion of Lourdes Felix to CEO; Brady Granier to Serve as President Anaheim, CA – (NewMediaWire) – November…
Read More » -
One-month of dual anti-platelet therapy is safe and feasible after stent placement
[ad_1] Research Highlights: A short, one-month treatment combining antiplatelet medication and aspirin followed by an aspirin-only regime was as effective…
Read More » -
Omega-3s did not reduce cardiac events in recent heart attack survivors
[ad_1] Research Highlights Omega-3 supplements in commonly available forms appear to be ineffective in preventing further cardiovascular events among elderly…
Read More »